Biofarm (BSE:BIO) General and Admin. Expense: lei1.7 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:BIO Biofarm SA BSE:BIO
70 GF Score
Price lei1.31
GF Value lei0.87
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biofarm General and Admin. Expense?

Biofarm BSE:BIO -4.74% 70 General and Admin. Expense is lei1.7 Mil as of Mar. 2026. GuruFocus rates BSE:BIO with a GF Score™ of 70/100 and a GF Value™ of lei0.87 (Significantly Overvalued). The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Biofarm's General and Admin. Expense for the three months ended in Mar. 2026 was lei0.5 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was lei1.7 Mil.

Biofarm General and Admin. Expense Related Terms

Biofarm General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Biofarm's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofarm General and Admin. Expense Chart

Biofarm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.55 1.49 1.56 1.63 1.69

Biofarm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.44 0.41 0.41 0.45
BSE:BIO
70GF Score
Biofarm SA BSE:BIO
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofarm General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei1.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of lei1.7 Mil mean?
Biofarm (BSE:BIO) has a General and Admin. Expense of lei1.7 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Biofarm and its competitors.
Is Biofarm's General and Admin. Expense too high?
Biofarm's current General and Admin. Expense is lei1.7 Mil. Overall, Biofarm has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofarm's General and Admin. Expense compare to ZTS and UTHR?
Biofarm's General and Admin. Expense of lei1.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Drug Manufacturers company?
A good General and Admin. Expense depends on the Drug Manufacturers industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Biofarm and its competitors. Biofarm's current General and Admin. Expense is lei1.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Based on GuruFocus' analysis, Biofarm (BSE:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is lei0.87, compared to a current price of lei1.31 — trading 50% above its estimated fair value. The current General and Admin. Expense is lei1.7 Mil. Biofarm's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Biofarm (BSE:BIO), the current General and Admin. Expense is lei1.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofarm (BSE:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of lei1.31 is trading 50% above its estimated GF Value™ of lei0.87. GuruFocus considers Biofarm to be Significantly Overvalued.

Key valuation signals for BSE:BIO:

  • General and Admin. Expense: lei1.7 Mil
  • GF Value™: lei0.87 vs. price of lei1.31 (50% above fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofarm Business Description

Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
70GF Score

Get the complete analysis for BSE:BIO

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei1.31
Price
lei0.87
GF Value